Increased risk and susceptibility factors for the development of thromboembolic events in individuals with sickle cell disease infected by Covid-19: an integrative review

Abstract

Introduction: in view of the concerns caused by the new Coronavirus pandemic and its disease (COVID-19), whether for health professionals or society in general, studies related to the risks for diseases with Sickle Cell Disease (SCD) are still scarce. Sickle cell disease has a state of hypercoagulability, even in stable patients, thus, an infection caused by COVID-19, possibly worsens the pathophysiological manifestations of these patients, which can have fatal consequences. Objective: to identify thromboembolic events caused by COVID-19, which are frequent in the SCD and can cause complications for these individuals, with a consequent increase in the risk of mortality. Methodology: integrative review, in which 278 studies were identified, of which 264 were excluded, and 14 articles were then kept, and they were categorized according to the design established for each of these studies, considering as quality criteria the items written in PEDro scale, associated with other criteria suggestive of good quality articles, such as H Index, impact factor, representativeness of authors in the study area and institutions, such as which these authors are linked to. Results: based on the information described, an increased risk of patients with sickle cell disease for the development of serious thromboembolic events exposed to exposure to COVID-19 was identified. Conclusion: people diagnosed with Sickle Cell Disease if infected with COVID-19 have a higher risk and susceptibility to the development of thromboembolic complications, consequently enhancing their chances of mortality. Clinical studies on thromboembolic effects of COVID-19 in patients with DF are of great importance and must be encouraged.